{
    "Trade/Device Name(s)": [
        "Immunalysis 6-acetylmorphine Urine Enzyme Immunoassay",
        "Immunalysis 6-acetylmorphine Urine Calibrator",
        "Immunalysis 6-acetylmorphine Urine Controls"
    ],
    "Submitter Information": "Immunalysis Corporation",
    "510(k) Number": "K150275",
    "Predicate Device Reference 510(k) Number(s)": [
        "K102779"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG",
        "DKB",
        "DIF"
    ],
    "Summary Letter Date": "January 20, 2015",
    "Summary Letter Received Date": "February 4, 2015",
    "Submission Date": "March 6, 2015",
    "Regulation Number(s)": [
        "21 CFR 862.3650",
        "21 CFR 862.3200",
        "21 CFR 862.3280"
    ],
    "Regulation Name(s)": [
        "Opiate test system",
        "Clinical Toxicology Calibrator",
        "Clinical Toxicology Control Material"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "6-Acetylmorphine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Beckman Coulter AU 400e"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay (EIA)"
    ],
    "Methodologies": [
        "Homogeneous enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Immunalysis 6-Acetylmorphine Urine Enzyme Immunoassay, Calibrator, and Controls for qualitative detection of 6-acetylmorphine in urine",
    "Indications for Use Summary": "Qualitative analysis of 6-Acetylmorphine in human urine using automated clinical chemistry analyzers with preliminary results requiring confirmation by GC-MS or LC/MS; controls and calibrators for use in the assay",
    "fda_folder": "Toxicology"
}